AZN

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.02
Percentage change 0.03	%

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM PVAL TQQQ FVD DIHP DFIC PPH AVDE QYLD

Scroll to Statements

Index	NDX	P/E	28.82	EPS (ttm)	2.49	Insider Own	0.02%	Shs Outstand	3.10B	Perf Week	4.70%
Market Cap	222.46B	Forward P/E	14.09	EPS next Y	5.09	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-2.40%
Income	7.77B	PEG	2.58	EPS next Q	1.10	Inst Own	16.82%	Short Float	0.20%	Perf Quarter	2.11%
Sales	54.98B	P/S	4.05	EPS this Y	9.96%	Inst Trans	-1.58%	Short Ratio	1.02	Perf Half Y	-4.42%
Book/sh	13.23	P/B	5.42	EPS next Y	12.75%	ROA	7.45%	Short Interest	6.33M	Perf Year	-4.57%
Cash/sh	1.74	P/C	41.23	EPS next 5Y	11.15%	ROE	19.81%	52W Range	61.24 - 87.68	Perf YTD	9.48%
Dividend Est.	1.61 (2.25%)	P/FCF	19.40	EPS past 5Y	34.63%	ROI	11.28%	52W High	-18.18%	Beta	0.40
Dividend TTM	1.55 (2.16%)	Quick Ratio	0.70	Sales past 5Y	17.77%	Gross Margin	72.58%	52W Low	17.13%	ATR (14)	1.79
Dividend Ex-Date	Feb 21, 2025	Current Ratio	0.90	EPS Y/Y TTM	18.11%	Oper. Margin	20.63%	RSI (14)	56.72	Volatility	1.95% 2.92%
Employees	94300	Debt/Eq	0.77	Sales Y/Y TTM	15.48%	Profit Margin	14.14%	Recom	1.38	Target Price	92.32
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	33.73%	Payout	66.98%	Rel Volume	0.43	Prev Close	71.71
Sales Surprise	-1.60%	EPS Surprise	11.52%	Sales Q/Q	7.17%	Earnings	Apr 29 BMO	Avg Volume	6.23M	Price	71.73
SMA20	4.76%	SMA50	-1.21%	SMA200	-2.61%	Trades		Volume	1,718,472	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Today 12:03PM	Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC (Clinical Trials Arena)
07:06AM	AstraZenecas Truqap fails in another Phase III trial (Pharmaceutical Technology)
03:06AM	AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
Apr-29-25 04:15PM	AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss (Investor's Business Daily)
04:10PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
02:26PM	Loading…
02:26PM	AstraZeneca CEO calls for increased European investment in pharma (Pharmaceutical Technology)
01:16PM	Pfizer CEO: 'We should not have tariffs' on pharma (Yahoo Finance)
12:05PM	AstraZeneca CEO: Trump tariffs 'not material long term' (Yahoo Finance)
11:46AM	AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha)
10:36AM	Buy our cancer drugs or jobs will go overseas, AstraZeneca warns (The Telegraph)
10:18AM	AstraZeneca's 'number 1 priority' is the US, CEO says (Yahoo Finance Video)
09:40AM	Here's Why Astrazeneca (AZN) is a Strong Value Stock (Zacks)
09:30AM	Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops (Investor's Business Daily)
09:12AM	AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs (Zacks)
07:00AM	Loading…
07:00AM	EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire)
05:40AM	AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China (The Wall Street Journal)
05:16AM	AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors (Reuters)
05:06AM	Astrazeneca: Q1 Earnings Snapshot (Associated Press Finance)
02:00AM	AstraZeneca's Q1 2025 Financial Results (Business Wire)
Apr-28-25 07:00PM	Coca-Cola earnings, JOLTS, Consumer Confidence: What to Watch (Yahoo Finance Video)
06:57PM	AstraZeneca PLC (OSTO:AZN) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
12:23PM	SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR (PR Newswire)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
06:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
01:29PM	Loading…
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
07:29AM	Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care (Pharmaceutical Business Review)
04:49AM	The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS (Zacks)
Apr-24-25 05:00PM	STAAR Surgical Announces Changes to Board of Directors (Business Wire)
03:00PM	Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? (Zacks)
02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
09:15AM	Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:59AM	Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth (Zacks)
07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
07:33AM	AstraZeneca enters $200m AI cancer pact with Tempus and Pathos (Pharmaceutical Technology)
06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-23-25 12:04PM	AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat (The Telegraph)
08:00AM	Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology (Business Wire)
05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-22-25 06:15PM	Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know (Zacks)
04:10PM	AstraZeneca rejoins leading U.S. drug lobby group after two-year absence (Reuters)
02:29PM	Regeneron to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
07:32AM	Merck Q1 Earnings Coming Up: Should You Buy the Stock Now? (Zacks)
05:50AM	Daiichi and AstraZenecas Enhertu shows PFS benefits in breast cancer trial (Clinical Trials Arena)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
01:36PM	Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? (Zacks)
08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
08:05AM	AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients (Benzinga)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer (Business Wire)
05:24AM	Enhertu combo tops standard drugs in first-line HER2 breast cancer (BioPharma Dive)
02:30AM	ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer (Business Wire)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
09:15AM	Selling America, Buying Europe - My Picks (Seeking Alpha)
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 08:56PM	Lilly Soars As Study Shows Weight-Loss Pill to Pass Ozempic (Bloomberg)
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
06:05AM	BGY: Underlying Fundamentals Can Be Improved (Seeking Alpha)
Apr-15-25 09:50PM	Parnassus Value Select ETF Q1 2025 Commentary (Seeking Alpha)
02:51PM	Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
05:39AM	Tariff wars to hit popular US-made drugs in China, regulator data shows (Reuters)
Apr-14-25 09:58AM	Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? (Insider Monkey)
03:06AM	Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now (Motley Fool)
02:17AM	The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis (Zacks)
Apr-12-25 09:32AM	GRAIL's Galleri Progresses While Back In Accumulation Levels (Seeking Alpha)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
11:47AM	Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More (Zacks)
07:40AM	AstraZenecas oral breast cancer drug Truqap greenlit for NHS use (Pharmaceutical Technology)
Apr-10-25 08:54AM	Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Apr-09-25 05:29PM	AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade) (Seeking Alpha)
12:03PM	Top Stock Movers Now: Delta, Apple, Eli Lilly, and More (Investopedia)
11:11AM	Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today (Motley Fool)
10:28AM	Pharma Stocks Sink as Trump Says 'Major' Tariffs Coming to Industry (Investopedia)
08:17AM	Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs (The Wall Street Journal)
06:17AM	Pharma Stocks Drop After Trump Threatens Tariffs on Medicines (The Wall Street Journal)
05:40AM	Trump Says Pharmaceutical Tariffs Coming Very Shortly (Bloomberg)
05:10AM	3 No-Brainer Growth Stocks to Buy for Less Than $100 (Motley Fool)
Apr-08-25 06:15PM	Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know (Zacks)
09:03AM	AstraZenecas camizestrant gains momentum, but questions remain as first-line therapy (Clinical Trials Arena)
Apr-07-25 07:40PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
12:09PM	Thornburg International Growth Fund Q4 2024 Commentary (Seeking Alpha)
10:53AM	AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs (Zacks)
06:37AM	EC approves AstraZenecas Imfinzi combo for NSCLC (Pharmaceutical Technology)
Apr-05-25 02:21AM	AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy (Seeking Alpha)
Apr-04-25 02:02PM	European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings (Benzinga) -7.39%
10:41AM	Daiichi and AstraZenecas Enhertu gains EC approval for breast cancers (Pharmaceutical Technology)
09:46AM	Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure (Zacks)
Apr-03-25 04:50PM	Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday (Motley Fool)
03:15PM	Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market (Seeking Alpha)
10:28AM	Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs (The Wall Street Journal)
Apr-01-25 10:44PM	Q4 2024 AIM ImmunoTech Inc Earnings Call (Thomson Reuters StreetEvents)
02:34PM	Impax International Sustainable Economy Fund Q4 2024 Commentary (Seeking Alpha)
12:05PM	AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial (TipRanks)
09:31AM	AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication (Zacks)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc ADR

Upgrade your FINVIZ experience